NextCell Pharma AB (fra:65G) Share Price

Company Profile

Business description
NextCell Pharma AB is a Swedish clinical-stage biotechnology company developing mesenchymal stromal cell (MSC)-based therapies for autoimmune and inflammatory diseases, with a primary focus on Type 1 Diabetes. Its key product candidate, ProTrans, is designed to preserve insulin-producing capacity in Type 1 Diabetes patients, while the company also operates Cellaviva, Scandinavia's private stem-cell bank, and QVance, which provides analytical and quality-control services for therapy medicinal products. It's operations are organized into three business areas: ProTrans (cell therapy development), Cellaviva (stem-cell banking), and QVance (ATMP analytical services). The company's activities are concentrated in Sweden and the Nordic region.
Contact
Karolinska Institutet Science Park
Halsovagen 7
Huddinge14157
SWE
T: +46 87355595
https://www.nextcellpharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
24

Recommended

Shares jumped 9% after earnings, as stronger AI memory prices boosted the chipmaker’s outlook.

Jing Jie Yu | 28 October 2026

Concerns about equity sales to finance AI investments have pressured shares.

Malik Ahmed Khan, CFA | 28 October 2026

AI data center revenue is growing fast, but questions about durability remain.

Nicolas Owens | 28 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,993.00	21.60	0.24%
CAC 40	7,886.96	0.18	-0.00%
DAX 40	25,704.02	113.25	0.44%
Dow JONES (US)	52,475.10	97.53	0.19%
FTSE 100	10,694.50	7.96	0.07%
HKSE	23,094.83	53.51	0.23%
NASDAQ	26,549.85	72.04	0.27%
Nikkei 225	64,634.81	680.62	1.06%
NZX 50 Index	13,725.74	34.41	0.25%
S&P 500	7,743.98	21.38	0.28%
S&P/ASX 200	8,871.60	24.30	0.27%
SSE Composite Index	3,681.46	0.00	-0.00%